Io­n­is col­lab­o­ra­tor Flamin­go is ready to take flight with 3 an­ti­sense drugs in the clin­ic and mys­te­ri­ous RNA in its sights

As the biggest name in an­ti­sense tech­nol­o­gy, Io­n­is has long fo­cused on test­ing the in­ter­play be­tween oligonu­cleotides and RNA for ther­a­peu­tic ef­fect. But one class of RNA has most­ly stumped re­searchers — un­til now.

Flamin­go Ther­a­peu­tics of­fi­cial­ly de­buted Thurs­day with three clin­i­cal and one pre­clin­i­cal can­cer drugs hand­ed off from an­ti­sense gu­ru Io­n­is, and an in­trigu­ing if un­proven dis­cov­ery en­gine gun­ning for mys­te­ri­ous long non-cod­ing RNA tar­gets.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER